Parse Biosciences collaborates with Hamilton, Opentrons Labworks and SPT Labtech
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced it has launched its Laboratory Automation Provider Program, enabling automation providers to readily support the adoption of Parse’s Evercode™ single cell products. By combining powerful automation with the Parse Evercode platform, customers will have unprecedented access to high-throughput single cell sequencing, […]
Kenai Therapeutics announces USD 82Mln series A financing
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of allogeneic neuron replacement cell therapies for neurological disorders, today announced an $82 million Series A financing co-led by Alaska Permanent Fund Corporation, Cure Ventures and The Column Group, with participation from Euclidean Capital and Saisei Ventures. […]
STEMCELL Technologies to acquire all assets of SQZ Biotechnologies Company
STEMCELL Technologies announced the acquisition of substantially all assets of SQZ Biotechnologies Company (SQZ)—a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them (mechanoporation) rather than using electricity (electroporation). This transaction, which was approved by SQZ shareholders today, marks another significant milestone for STEMCELL, Canada’s […]
Bayer AG Inaugurates First Cell Therapy MFTG Facility In California
Bayer AG recently announced the inauguration of its first Cell Therapy Launch or Manufacturing Facility (MFTG) in Berkeley, California to create a capacity to bring cell therapies to patients on a global scale. Industry sources added that this USD$250 million, 100,000-square-foot facility will supply the material required for late-stage clinical trials and potential commercial launch […]
